Overview

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness and safety of single agent pazopanib in subjects with chondrosarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
George Clinical Pty Ltd
Vector Oncology
Collaborator:
GlaxoSmithKline